The effect of flutamide on systemic and renal hemodynamics in Zucker diabetic rats: paradoxic renal vasodilator response to endothelin-1 and TXA2 receptor activation in female sex.

Abstract:

BACKGROUND:There is increasing evidence that endogenous sex hormones regulate vascular reactivity, and testosterone may contribute to the worse prognosis for renal disease in men. Male Zucker diabetic rats exhibit improved renal hemodynamic responses after castration. It is, however, unclear whether endogenous testosterone affects renal and systemic microcirculatory responses in the female sex, especially in type 2 diabetes. AIM:To test the hypothesis that endogenous testosterone in the female Zucker diabetic rat exerts a pathophysiologically relevant modulation of endothelial and renal microvascular function. METHODS:Female Zucker diabetic rats (FZDR) aged 5-6 weeks and from the same litter were divided into 2 groups (n = 6-8 each). The experimental group received the androgen receptor blocker flutamide, dissolved in alcohol and added to their drinking water (500 mL) at 20 mg/rat/week. The control FZDR received only the alcohol vehicle added to the same volume of drinking water. Both FZDR groups were treated for 3 months before undergoing the hemodynamic studies. A sex comparison control group of male Zucker diabetic rats (MZDR), also aged 5-6 weeks, was studied, following same protocol. Mean arterial pressure (MAP) and renal cortical blood flow (RCF) response to phenylephrine, acetylcholine, TXA2-mimetic U46619, endothelin-1 (ET-1), angiotensin II, and L-NG-nitro arginine methyl ester were studied. Furthermore, the role of protein kinase C in the responses was assessed using phorbol-12,13 dibutyrate 10(-4) M. The impact of flutamide on body weights and blood glucose of the rats were also determined. RESULTS:Flutamide-treated FZDR had a significant reduction in body weight/adiposity to 432 +/- 44 g, compared to controls at 553 +/- 37 g (P = 0.045), and random blood glucose concentration of 185 +/- 44 g/dL, compared to the control FZDR at 475 +/- 34 g/dL (P = 0.002). Vehicle-treated FZDR (n = 6-8), exhibited little or no systemic or renal response to any of the agonists. By contrast, flutamide treatment of FZDR (n = 5-7) caused a normalization of the dose-dependent MAP and RCF pressor response to phenylephrine [P < 0.005, analysis of variance (ANOVA)] and the vasodilator response to acetylcholine (P <. 0.01, ANOVA). Flutamide-treated FZDR showed enhanced pressor response to U46619 (P = 0.024, ANOVA), ET-1, and angiotensin II (P < 0.03, ANOVA). Surprisingly, the augmented systemic pressor action of U46619 and ET-1 was accompanied by a renal vasodilator action, with paradoxic RCF increases to U46619 (P < 0.003, ANOVA) and to ET-1 (P < 0.001, ANOVA) only in flutamide-treated FZDR. By contrast, flutamide-treated MZDR exhibited no significant change in body weight and an attenuation of the vasoconstrictor responses and enhanced nitric oxide-mediated dilatation compared with male controls. However, no specific effect on ET-1 or TXA2 receptor-mediated renal perfusion was discernible. Both L-NG-nitro arginine methyl ester and the protein kinase C agonist phorbol-12,13 dibutyrate [10(-4)M] significantly increased MAP and reduced RCF (P < 0.03) in the experimental FZDR compared with their controls. CONCLUSION:Flutamide administration to FZDR resulted in the reversal of abnormal systemic and renal alpha-1-mediated vasoconstriction and enhanced nitric oxide-mediated vasodilation. Flutamide caused a paradoxic but specific increase in renal perfusion during ET-1 and TXA2 receptor activation, which could be renoprotective in females. The salutary effects of flutamide on vascular reactivity in the FZDR may be mediated by a protein kinase C-dependent mechanism. These results are compatible with the notion that endogenous testosterone may regulate systemic and renal microcirculation in the female sex and in the type 2 diabetic state.

journal_name

J Cardiovasc Pharmacol

authors

Ajayi AA,Fidelis P

doi

10.1097/01.fjc.0000246941.84607.11

subject

Has Abstract

pub_date

2006-11-01 00:00:00

pages

191-8

issue

5

eissn

0160-2446

issn

1533-4023

pii

00005344-200611000-00001

journal_volume

48

pub_type

杂志文章
  • Sevoflurane and bradykinin-induced calcium mobilization in pulmonary arterial valvular endothelial cells in situ: sevoflurane stimulates plasmalemmal calcium influx into endothelial cells.

    abstract::Kinins locally synthesized in the cardiovascular tissue are believed to contribute to the regulation of cardiovascular homeostasis by stimulating the endothelial cells to release nitric oxide, prostacyclin, or a hyperpolarizing factor via autocrine-paracrine mechanisms. This study was designed to investigate the actio...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:10.1097/00005344-200211000-00009

    authors: Kanna T,Akata T,Izumi K,Nakashima M,Yonemitsu Y,Hashizume M,Takahashi S

    更新日期:2002-11-01 00:00:00

  • Intravenous dilevalol in the treatment of severe hypertension.

    abstract::Dilevalol, the stereoisomer of labetalol, was given in repeated incremental intravenous bolus injections to 10 patients with severe hypertension requiring urgent blood pressure lowering. The mean cumulative dose of dilevalol was 445 +/- 165 mg. Blood pressure was reduced from 201 +/- 33/131 +/- 13 to 150 +/- 12/109 +/...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:

    authors: Bursztyn M,Gavras I,Blasucci DJ,Gavras H

    更新日期:1989-05-01 00:00:00

  • Pharmacological characteristics of beta blockers and their role in clinical practice.

    abstract::Since beta-adrenoceptor blocking drugs were originally discovered and shown to be important therapeutic agents in the management of both angina pectoris and hypertension, many other similar drugs have become available. These share the common property of beta-adrenoceptor antagonism, though they may vary in terms of po...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00005344-198608006-00002

    authors: McDevitt DG

    更新日期:1986-01-01 00:00:00

  • Attenuation of experimental subarachnoid hemorrhage-induced cerebral vasospasm by CGS 26303, an endothelin-converting enzyme inhibitor.

    abstract::The effect of CGS 26303, an endothelin-converting enzyme inhibitor, on the prevention and reversal of cerebral vasospasm was investigated in a rabbit model of subarachnoid hemorrhage (SAH). In the prevention study, rabbits were injected with 3 ml of autologous blood in the cisterna magna and treatment with CGS 26303 i...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:10.1097/00005344-199800001-00089

    authors: Kwan AL,Bavbek M,Jeng AY,Toyoda T,Kassell NF,Lee KS

    更新日期:1998-01-01 00:00:00

  • Effects of beta-adrenergic blockade on the glomerular and tubular response to acute renal denervation.

    abstract::Using micropuncture techniques in euvolemic adult male Munich-Wistar rats, we assessed the functional role of renal beta-adrenoceptors in mediating neural control of glomerular filtration and proximal tubular reabsorption. The determinants of nephron filtration and rate of proximal tubular reabsorption were measured i...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:10.1097/00005344-199103000-00007

    authors: Thomson SC,Tucker BJ,Blantz RC

    更新日期:1991-03-01 00:00:00

  • Orally administered rapamycin does not modify rat aortic vascular tone.

    abstract::Rapamycin (RP; rapamune, sirolimus) is a potent inhibitor of vascular smooth muscle cell proliferation and migration. RP was demonstrated to reduce vascular neointimal formation in different animal models of vascular smooth muscle cell proliferation, and clinical use of RP-eluting stents promotes significant reduction...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:10.1097/FJC.0b013e31802e6420

    authors: Neto Mde M,Di Marco GS,Casarini DE,Lima VC,Campos AH

    更新日期:2007-02-01 00:00:00

  • Erythropoietin Improves Cardiovascular Function in Adult Rats After Acute Hemorrhage.

    abstract::Erythropoietin (EPO) has been linked to cardioprotective effects. However, its effects during the aging process are little known. We investigated the effect of EPO administration on hemodynamic parameters, cardiac function, oxidative damage, and erythropoietin receptor (EPOR) expression pattern in the hypovolemic stat...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:10.1097/FJC.0000000000000666

    authors: Puchulu MB,Arreche N,Zotta E,Donato M,Ogonowski N,Fellet A,Balaszczuk AM

    更新日期:2019-05-01 00:00:00

  • Phase 1B, Randomized, Double-Blinded, Dose Escalation, Single-Center, Repeat Dose Safety and Pharmacodynamics Study of the Oral NLRP3 Inhibitor Dapansutrile in Subjects With NYHA II-III Systolic Heart Failure.

    abstract:ABSTRACT:The NLRP3 inflammasome has been implicated in the development and progression of heart failure. The aim of this study was to determine the safety of an oral inhibitor of the NLRP3 inflammasome, dapansutrile (OLT1177), in patients with heart failure and reduced ejection fraction (HFrEF). This was a phase 1B, ra...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:10.1097/FJC.0000000000000931

    authors: Wohlford GF,Van Tassell BW,Billingsley HE,Kadariya D,Canada JM,Carbone S,Mihalick VL,Bonaventura A,Vecchié A,Chiabrando JG,Bressi E,Thomas G,Ho AC,Marawan AA,Dell M,Trankle CR,Turlington J,Markley R,Abbate A

    更新日期:2020-10-24 00:00:00

  • Interaction of the beta adrenergic receptor antagonist bucindolol with serotonergic receptors.

    abstract::Bucindolol is a nonselective beta-adrenergic receptor antagonist that has additional vasodilating properties. Because some beta-adrenergic receptor antagonists such as cyanopindolol are used as 5-HT1A/5-HT1B receptor antagonists, we tested the hypothesis that bucindolol can interact with 5-HT receptors. Both in vitro ...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:10.1097/00005344-200001000-00004

    authors: Watts SW,Fink GD,Silver PJ,Cushing DJ

    更新日期:2000-01-01 00:00:00

  • Effect of veratric acid on the cardiovascular risk of L-NAME-induced hypertensive rats.

    abstract::Hypertension is associated with dyslipidemia, which is a significant risk factor for cardiovascular complications. This study was undertaken to investigate the effects of veratric acid (VA) on blood pressure, plasma, and tissue lipid profile in N-nitro-L-arginine methyl ester (L-NAME)-induced hypertensive rats. Hypert...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:10.1097/FJC.0b013e31824f9174

    authors: Saravanakumar M,Raja B

    更新日期:2012-06-01 00:00:00

  • Intravenous and oral antiplatelet/antithrombotic efficacy and specificity of XR300, a novel nonpeptide platelet GPIIb/IIIa antagonist.

    abstract::Currently used antiplatelet drugs including aspirin, ticlopidine, and others are effective against certain but not all of the many endogenous platelet activators. Because of their limited efficacy, a significant number of serious thromboembolic complications still occur, highlighting the need for a more effective ther...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:10.1097/00005344-199803000-00016

    authors: Mousa SA,Forsythe M,Wityak J,Bozarth J,Mu DX

    更新日期:1998-03-01 00:00:00

  • Inhibitors of phosphodiesterase (pentoxifylline, trequinsin) inhibit apical and subcellular matrix expression of tissue factor in cultured human endothelial cells.

    abstract::Exposure of endothelial cells (ECs) to thrombin or cytokines leads to major changes in their biochemical properties, which confer procoagulant activities. Stimulated ECs express the procoagulant glycoprotein tissue factor (TF). Although some TF is expressed on the apical surface of the cells, most is deposited as a cr...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:10.1097/00005344-199500252-00019

    authors: Leclerc NE,Haan-Archipoff G,Lenoble M,Beretz A

    更新日期:1995-01-01 00:00:00

  • Felodipine compared to prazosin as additional therapy to a beta-blocking drug.

    abstract::Felodipine was compared with prazosin in patients with essential hypertension whose blood pressure was not controlled by a beta-blocking drug. One hundred patients with a supine diastolic blood pressure greater than or equal to mm Hg after 4 weeks or more on a beta-blocking drug and placebo were randomly assigned to f...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Chalmers J,Wing L,West M,Bune A,Johnston C,Jackson B,McGrath B,Mashford ML,Heath W,Westwood B

    更新日期:1987-01-01 00:00:00

  • The effect of antihypertensive treatment on electrocardiogram voltages in the EWPHE trial.

    abstract::Long-term effects of antihypertensive treatment on various electrocardiogram (ECG) voltages and the association between ECG findings at randomization and subsequent mortality were evaluated in the double-blind, placebo-controlled trial of elderly hypertensive patients, conducted by the European Working Party on High B...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00005344-199117002-00020

    authors: Van Hoof R,Staessen J,Fagard R,Thijs L,Amery A

    更新日期:1991-01-01 00:00:00

  • Mechanism underlying relaxations caused by prostaglandins and thromboxane A2 analog in isolated dog arteries.

    abstract::In helical strips of dog cerebral, coronary, mesenteric, and renal arteries treated with ONO3708, an inhibitor of vasoconstricting prostaglandin (PG) receptors, and previously contracted with serotonin, PGF2 alpha, PGD2 and epithio-methano thromboxane A2 (sTxA2), a TxA2 analog, caused a relaxation. The cerebral arteri...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:10.1097/00005344-198803000-00014

    authors: Toda N,Inoue S,Okamura T,Okunishi H

    更新日期:1988-03-01 00:00:00

  • Inhibition of FGFR Signaling With PD173074 Ameliorates Monocrotaline-induced Pulmonary Arterial Hypertension and Rescues BMPR-II Expression.

    abstract:BACKGROUND:Numerous studies have demonstrated that fibroblast growth factor-2 (FGF-2) signaling may play a pivotal role in the development of pulmonary arterial hypertension (PAH). Excessive endothelial FGF-2 contributes to smooth muscle hyperplasia and disease progression. PD173074 is a potent FGF receptor 1 (FGFR-1) ...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:10.1097/FJC.0000000000000302

    authors: Zheng Y,Ma H,Hu E,Huang Z,Cheng X,Xiong C

    更新日期:2015-11-01 00:00:00

  • Acetylcholinesterase inhibitor (donepezil hydrochloride) reduces heart rate variability.

    abstract::An acetylcholinesterase inhibitor (donepezil hydrochloride) has recently been used for the treatment of senile dementia of Alzheimer type. The effect of this acetylcholinesterase inhibitor on the autonomic nervous control of the heart was investigated in 17 patients with senile dementia of Alzheimer type. Donepezil ad...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:

    authors: Masuda Y,Kawamura A

    更新日期:2003-01-01 00:00:00

  • Endocrine and vascular responses in hypertensive patients to long-term treatment with diltiazem.

    abstract::Forty patients (aged 28-66 years) with essential hypertension were randomized to 14 weeks of treatment with diltiazem or hydrochlorothiazide (HCTZ) in a double-blind, parallel study design. A significant reduction in supine body weight (-6.0 +/- 1.5 lb; p less than 0.001) and increase in pulse (+6 +/- 2 beats/min; p l...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00005344-198704000-00002

    authors: Swartz SL

    更新日期:1987-04-01 00:00:00

  • Differing dosages of captopril and hydrochlorothiazide in the treatment of hypertension: long-term effects metabolic values and intracellular electrolytes.

    abstract::The effects of long-term treatment with differing dosages of captopril and hydrochlorothiazide in combination were evaluated in 22 hypertensive patients. There was no significant difference in antihypertensive efficacy between captopril 25 mg twice a day in combination with hydrochlorothiazide 25 mg once or twice dail...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00005344-198507001-00014

    authors: Costa FV,Borghi C,Boschi S,Ambrosioni E

    更新日期:1985-01-01 00:00:00

  • The once-daily dose regimen of carvedilol: a meta-analysis approach.

    abstract::Establishing the overall efficacy or safety of a drug requires a unified methodological approach and analysis of all clinical trials that are intended to be summarized. As an example, this article presents the aggregated dose-response relationship and a subgroup analysis (by age) over all studies of the antihypertensi...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 临床试验,杂志文章,meta分析

    doi:10.1097/00005344-199219001-00025

    authors: Stienen U

    更新日期:1992-01-01 00:00:00

  • A double-blind comparison of amlodipine and placebo added to open enalapril in patients with moderate to severe essential hypertension.

    abstract::The antihypertensive efficacy and tolerability of amlodipine in combination with enalapril were assessed in this two-center study. Patients with moderate to severe hypertension and with diastolic blood pressure > 95 mm Hg after 4 weeks of treatment with open-label enalapril 5-10 mg daily were randomized to receive aml...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1097/00005344-199117001-00006

    authors: Davies J,Jensen H,Garsdal P

    更新日期:1991-01-01 00:00:00

  • R56865, a potent new antiarrhythmic agent, effective during ischemia and reperfusion in the rat heart.

    abstract::The antiarrhythmic effects of R56865 were characterized both in vivo and in vitro. Four groups (n = 12 per group) of anesthetized rats, subjected to 5- or 30-min coronary artery ligation and reperfusion, were studied: saline, dimethyl sulfoxide (DMSO) carrier, and R56865 (0.5 or 2 mg/kg) were administered as an intrav...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:10.1097/00005344-199009000-00018

    authors: Garner JA,Hearse DJ,Bernier M

    更新日期:1990-09-01 00:00:00

  • Cardioprotective Effects of Atorvastatin Are Mediated Through PPARγ in Paraquat-Exposed Rats.

    abstract:BACKGROUND:Paraquat poisoning is one of leading intoxication worldwide without an effective antidote and treatment protocol. Among the other organs, cardiotoxicity of paraquat has been frequently reported. AIM:The protective effects of atorvastatin (STN) on paraquat-induced cardiotoxicity and the role of peroxisome pr...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:10.1097/FJC.0000000000000731

    authors: Malekinejad M,Masoumi Verki M,Khoramjouy M,Alenabi A,Hallaj-Salahipour M,Malekinejad H

    更新日期:2019-11-01 00:00:00

  • Excretory responses to renal nerve stimulation during inhibition of neutral metalloendopeptidase and angiotensin-converting enzyme in the rat.

    abstract::To evaluate the interaction between renal nerves, the atrial natriuretic peptide (ANP), and the renin-angiotensin system (RAS), electrical stimulation of renal nerves was performed in spontaneously hypertensive rats (SHR) and in their normotensive controls, Wistar Kyoto rats (WKY), before and after pharmacologic treat...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:10.1097/00005344-199611000-00009

    authors: Golin R,Protasoni G,Wjinmaalen P,Sala C,Monopoli A,Casati C,Zanchetti A,Stella A

    更新日期:1996-11-01 00:00:00

  • Antihypertensive and renal vasodilator effect of diltiazem in DOCA-salt hypertensive dog.

    abstract::We studied the effect of an intravenous (i.v.) infusion of diltiazem (15 micrograms/kg/min) given for 1 week on several cardiovascular parameters, renal blood flow, and electrolyte and urinary excretion in chronically instrumented DOCA-salt hypertensive dogs. On the first recording session, 24 h after diltiazem infusi...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:10.1097/00005344-198806000-00015

    authors: Zimmerman BG,Goering JL,Raich PC

    更新日期:1988-06-01 00:00:00

  • Electromechanical dissociation after ventricular fibrillation: prevention with calcium-entry blockers.

    abstract::Calcium-entry blockers were administered in an attempt to protect myocardium during cardiac arrest due to ventricular fibrillation in mechanically ventilated dogs. An intravenous injection of verapamil, nifedipine, or lidoflazine was administered prior to successively prolonged episodes of ventricular fibrillation, du...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:

    authors: Vincent JL,Goldstein J,Dufaye P,Domb M

    更新日期:1984-11-01 00:00:00

  • Physical activity and the metabolic cardiovascular syndrome.

    abstract::Hyperinsulinemia, lipid abnormalities, and impaired fibrinolytic capacity may accompany hypertension, and comprise the metabolic cardiovascular syndrome. They are all independent risk factors for coronary artery disease. Lifestyle modifications can reduce the coronary artery risk. Physical activity has been shown to i...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章,评审

    doi:

    authors: Westheim A,Os I

    更新日期:1992-01-01 00:00:00

  • Cardioprotective aspects of calcium antagonists.

    abstract::The use of calcium antagonists as cardioprotective agents is based on the assumption that uncontrolled Ca2+ gain is a key factor in causing cell death and tissue necrosis. This uncontrolled gain in Ca2+ is the ultimate expression of a series of metabolic events triggered by inadequate perfusion. One of the early event...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:

    authors: Nayler WG

    更新日期:1991-01-01 00:00:00

  • W1, a Novel Oral Antiplatelet Agent With Less Resistance Than Clopidogrel.

    abstract::Clopidogrel (CLO) is a clinical antiplatelet agent, about which there are major concerns because its antiplatelet efficiency decreases with insufficient metabolic activation, leading to "clopidogrel resistance." We aimed to determine the antiplatelet effects of W1, a novel molecule composed of 2-O-clopidogrel and aspi...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:10.1097/FJC.0000000000000449

    authors: Ge P,Du L,Han C,Li H,Feng Y,Han J,Wang Z,Xiong L,Yuan M,Liu Y

    更新日期:2017-02-01 00:00:00

  • Future directions for randomized trials of cardiovascular disease prevention in hypertensive patients.

    abstract::Coronary artery disease (CAD) is the major cause of death in hypertensive patients in Western populations and further efforts are required to determine how best to reduce its incidence. Large-scale placebo-controlled trials of blood pressure reduction could resolve the uncertainty about the effects of antihypertensive...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章,评审

    doi:

    authors: MacMahon S,Sharpe N

    更新日期:1990-01-01 00:00:00